The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Mar 2016 10:34

RNS Number : 0284T
Hutchison China Meditech Limited
23 March 2016
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Hutchison China MediTech Limited

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Change in total voting rights of the issuer

ü

3. Full name of person(s) subject to thenotification obligation: iii

Hutchison Healthcare Holdings Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

22 March 2016

6. Date on which issuer notified:

22 March 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

64%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

36,666,667

36,666,667

36,666,667

36,666,667

60.82

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

36,666,667

60.82%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Hutchison Healthcare Holdings Limited is a wholly owned subsidiary of Hutchison Whampoa (China) Limited, which is an indirect wholly-owned subsidiary of CK Hutchison Holdings Limited - 36,666,667 ordinary shares (60.82%)

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Edith Shih

15. Contact telephone number:

+852 2128 1232

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOURRNVAOUAR
Date   Source Headline
12th May 20231:15 pmRNSAnnual General Meeting Poll Results
12th May 20239:30 amRNSBoard of Directors and Board Committee Membership
10th May 20239:30 amRNSAppointment of Independent NED
28th Apr 20239:30 amRNSTotal Voting Rights
21st Apr 20239:30 amRNSVesting of awards under the LTIP
18th Apr 20237:00 amRNSNDA Acceptance in China for Fruquintinib
12th Apr 20237:00 amRNSPresentations at AACR Annual Meeting 2023
11th Apr 20239:30 amRNSIntended Retirement of Independent NED
11th Apr 20239:30 amRNS2022 Annual Report and Notice of AGM
4th Apr 202310:30 amRNSHUTCHMED Initiates Registration Phase Enrollments
31st Mar 20239:30 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSRolling Submission of Fruquintinib US NDA Complete
14th Mar 20231:30 pmRNSClosing of Fruquintinib License to Takeda
8th Mar 20238:30 amRNSDirector's Share Dealing
6th Mar 20238:30 amRNSVesting of awards under the LTIP
28th Feb 202312:15 pmRNSPublication of Form 20-F
28th Feb 20238:30 amRNS2022 Full Year Results and Business Updates
27th Feb 202310:00 amRNSEnrollment Completed in Phase 2 Amdizalisib trial
31st Jan 20238:30 amRNSNotice of Results
23rd Jan 20238:00 amRNSLicense to Takeda for Fruquintinib outside China
18th Jan 20232:30 pmRNSInclusion of ORPATHYS in NRDL in China
3rd Jan 20238:30 amRNSEnrollment Completed in Phase 3 Trial
30th Dec 20228:30 amRNSBlocklisting Six Monthly Return
19th Dec 202210:00 amRNSFDA NDA Rolling Submission for Fruquintinib
15th Nov 20227:00 amRNSHUTCHMED Announces Strategy Update
14th Nov 20227:00 amRNSPositive Topline Phase 3 Result in Fruquintinib
27th Oct 202212:30 pmRNSHUTCHMED Initiates Phase 2/3 Trial of Fruquintinib
21st Oct 20229:30 amRNSVesting of awards under the LTIP
10th Oct 20229:30 amRNSPhase II/III Trial of Sovleplenib for in China
30th Sep 20229:30 amRNSTotal Voting Rights
14th Sep 202211:00 amRNSShare Option Scheme and Long Term Incentive Plan
8th Sep 20227:00 amRNSFRESCO-2 Colorectal Cancer MRCT Data Highlights
23rd Aug 202210:00 amRNSHolding(s) in Company
23rd Aug 20229:30 amRNSHUTCHMED To Present FRESCO-2 Data at ESMO 2022
9th Aug 20229:30 amRNSFirst Participant in Phase I Trial of IMG-004
8th Aug 20229:30 amRNSPreliminary results from SAVANNAH Phase 2 Trial
8th Aug 20227:00 amRNSFRESCO-2 Study Has Met Primary Endpoint
1st Aug 202212:04 pmRNSInterim Results and Business Updates
1st Aug 20227:00 amRNSHUTCHMED Initiates Bridging Study of Tazemetostat
15th Jul 20229:30 amRNSHUTCHMED Initiates Phase I Trial of HMPL-A83
13th Jul 20227:00 amRNSResults of SAVANNAH Global Phase II Trial at WCLC
6th Jul 20227:00 amRNSFirst Participants in Phase I Trial of IMG-007
30th Jun 20229:30 amRNSTotal Voting Rights
29th Jun 20229:30 amRNSBlocklisting Six Monthly Return
27th Jun 20229:30 amRNSHUTCHMED to Announce 2022 Half-Year Results
1st Jun 20229:30 amRNSTAZVERIK® Approved in Hainan Pilot Zone
24th May 202211:00 amRNSLTIP and Share Options
16th May 202212:00 pmRNSAppointment of Non–Executive Director
3rd May 20227:00 amRNSHUTCHMED Receives CRL from the US FDA
27th Apr 20222:30 pmRNSAnnual General Meeting Poll Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.